Overview
This is a monocentric, comparative, open-label, randomized parallel group study enrolling elderly subjects hospitalized in Strasbourg Europe Cancerology Institute (ICANS), starting chemotherapy or targeted therapy for the treatment of digestive cancer.
Description
At the ICANS an EPODIG-G program, consisting in a coordination of supportive care that are existing in the Institute, is proposed to elderly patients with digestive cancer. The purpose of this study is to evaluate the impact of this early multidisciplinary geriatric program (EPODIG-G), when it is initiated before therapeutic treatment.
Eligibility
Inclusion Criteria:
- Patients must be ≥ 75 years old
- Performance status 0, 1 or 2
- Diagnostic of digestive cancer, all stages (adjuvant or metastatic), with an indication for chemotherapy treatment or targeted therapy
- Patients previously treated with one or several lines of chemotherapy for this digestive cancer are eligible
- Estimated life expectancy ≥ 3 months
- Patients able to speak, read and understand French
- Signed informed consent from the patient
- Patients must have a social security coverage
Exclusion Criteria:
- History of differentiated neuroendocrine tumors grade 1 or 2 (pancreas, small intestine)
- History of another treated cancer during the last five years
- History of major surgery and/or curative radiation therapy during the last 4 weeks before inclusion
- Patients unable to submit to medical follow-up for geographical, social or psychological reasons
- Patients placed under guardianship